A Phase 1/2 interventional study of TAK-019 and Placebo in Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), sponsored by Takeda. Completed at 2 sites in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-06.
Sponsored by Takeda · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
At the first visit, the study doctor will check if each person can take part. Those who can take part will be chosen for 1 of 2 treatments by chance. Participants will either receive an injection of TAK-019 or a placebo in their arm. In this study, a placebo will look like the TAK-019 vaccine but will not have any medicine in it. 3 times as many participants will receive TAK-019 than placebo. Participants will receive 2 injections of TAK-019 or placebo, 21 days apart.
Participants will be asked to record their temperature and any medical problems in an electronic diary for up to 7 days after each injection.
During the study, participants will visit the clinic for regular check-ups, blood tests, and sometimes for nose swab samples. When all participants have attended a clinic visit 28 days after their 2nd injection, the study sponsor (Takeda) will check how many participants have made enough antibodies to protect them against Covid-19.
The participants will stay in the study for up to 12 months after they have had their 2nd injection. During this time, the study doctors will continue to check how many participants have made enough antibodies to protect them against Covid-19. Also, they will check if participants have any more side effects from TAK-019 or the placebo.
The drug being tested in this study is called TAK-019. TAK-019 is being tested to prevent infectious disease caused by Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2). This study will look at the evaluate the safety and immunogenicity of 2 doses of TAK-019 by intramuscular (IM) injection 21 days apart in healthy Japanese male and female adults.
The study will enroll approximately 200 healthy volunteers. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take intramuscular injection in the upper arm twice throughout the study.
This multi-center trial will be conducted in Japan. The overall time to participate in this study is 12 months from the second vaccination (totally 387 days). Participants will make multiple visits to the clinic and will be contacted by telephone or a final visit after the last vaccination for a follow-up assessment.
376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.
This study's enrollment of 200 is above the median of 140 across 210 interventional studies indexed under Severe Acute Respiratory Syndrome.
Browse Severe Acute Respiratory Syndrome studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-019 0.5 mL, intramuscular injection in the upper arm
Biological: TAK-019
TAK-019 Matching Placebo, intramuscular injection in the upper arm
Biological: Placebo
TAK-019 intramuscular injection
Placebo intramuscular injection
Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination
Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited local AEs included injection site pain, tenderness, erythema/redness, induration, and swelling.
Time frame: Up to Day 7 (6 subsequent days after first vaccination on Day 1)
Percentage of Participants With Solicited Local AEs for Six Subsequent Days Following Second Vaccination
Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited local AEs included injection site pain, tenderness, erythema/redness, induration, and swelling.
Time frame: Up to Day 28 (6 subsequent days after second vaccination on Day 22)
Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following First Vaccination
Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited systemic AEs included fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.
Time frame: Up to Day 7 (6 subsequent days after first vaccination on Day 1)
Percentage of Participants With Solicited Systemic AEs for Six Subsequent Days Following Second Vaccination
Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited systemic AEs included fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.
Time frame: Up to Day 28 (6 subsequent days after second vaccination on Day 22)
Percentage of Participants With Unsolicited AEs for 20 Days Following First Vaccination
Unsolicited AEs were all AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary.
Time frame: Up to Day 21 (20 days after first vaccination on Day 1)
Percentage of Participants With Unsolicited AEs for 27 Days Following Second Vaccination
Unsolicited AEs were all AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary.
Time frame: Up to Day 49 (27 days after second vaccination on Day 22)
Percentage of Participants With Serious Adverse Events (SAEs) Until Day 50
Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this outcome measure (OM) and solicited SAE was out of the scope of assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs until Day 50 were reported in this outcome measure.
Time frame: Day 1 up to Day 50
Percentage of Participants With Adverse Events of Special Interest (AESI) Until Day 50
AESIs were defined as AEs that were specifically highlighted to the Investigator. Only unsolicited AESI data was planned to be collected and assessed for the assessment of this OM and solicited AESI was out of the scope of assessment. Unsolicited AESIs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited AESIs until Day 50 were reported in this outcome measure.
Time frame: Day 1 up to Day 50
Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 50
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAE was out of the scope of assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs until Day 50 were reported in this outcome measure.
Time frame: Day 1 up to Day 50
Percentage of Participants With Any AE Leading to Discontinuation of Vaccination
Only any unsolicited AE leading to discontinuation of vaccination data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to discontinuation of vaccination was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to discontinuation of vaccination until Day 22 were reported in this outcome measure.
Time frame: Day 1 up to Day 22
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 50
Only any unsolicited AE leading to participant's withdrawal from the trial data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal from the trial was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to participant's withdrawal from the trial until Day 50 were reported in this outcome measure.
Time frame: Day 1 up to Day 50
Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 50
Time frame: Day 1 up to Day 50
Geometric Mean Titers (GMT) of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 36
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 200. Here, ELISA is Enzyme-linked immunosorbent assay.
Time frame: At Day 36
Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36
GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Day 36
Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36
SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Day 36
Seroresponse Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36
SRR was defined as percentage of participants with greater than or equal to (\>=) 95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Day 36
Percentage of Participants With SAE Throughout the Trial
Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this OM and solicited SAE was out of the scope of assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs throughout the trial were reported in this outcome measure.
Time frame: Day 1 up to Day 387
Percentage of Participants With AESI Throughout the Trial
AESIs were defined as AEs that were specifically highlighted to the Investigator. Only unsolicited AESI data was planned to be collected and assessed for the assessment of this OM and solicited AESI was out of the scope of assessment. Unsolicited AESI were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited AESIs throughout the trial were reported in this outcome measure.
Time frame: Day 1 up to Day 387
Percentage of Participants With MAAEs Throughout the Trial
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAE was out of the scope of assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs throughout the trial were reported in this outcome measure.
Time frame: Day 1 up to Day 387
Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial
Only any unsolicited AE leading to participant's withdrawal from the trial data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal from the trial was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to withdrawal from the trial from the day of vaccination throughout the trial were reported in this outcome measure.
Time frame: Day 1 up to Day 387
Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial
Time frame: Day 1 up to Day 387
GMT of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. GMT of serum IgG antibody levels to the SARS-CoV-2 rS protein was measured where LLOQ was equal to 200.
Time frame: At Days 22, 50, 202, and 387
GMFR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387
GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Days 22, 50, 202, and 387
SCR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387
SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Days 22, 50, 202, and 387
SRR of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Days 22, 50, 202, and 387
SRR was defined as percentage of participants with \>=95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Days 22, 50, 202, and 387
GMT of Serum Neutralizing Antibody (nAb) Titers to Wild Type Virus on Days 22, 36, 50, 202 and Day 387
The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. GMT of serum IgG antibody levels to the SARS-CoV-2 rS protein was measured where LLOQ was equal to 20.
Time frame: At Days 22, 36, 50, 202 and 387
GMFR of Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387
The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Days 22, 36, 50, 202 and 387
SCR to Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387
The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at Baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Days 22, 36, 50, 202 and 387
SRR to Serum nAb Titers to Wild Type Virus on Days 22, 36, 50, 202 and 387
The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). SRR was defined as percentage of participants with \>=95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.
Time frame: At Days 22, 36, 50, 202 and 387
Participants took part in the study at 2 investigative sites in Japan from 12 February 2021 to 28 March 2022.
| Milestone | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Started | 50 | 150 |
| Completed | 4 | 131 |
| Not completed | 46 | 19 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Chose publicly available sars-cov-2 vaccine | 46 | 14 |
Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited local AEs included injection site pain, tenderness, erythema/redness, induration, and swelling.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Injection site pain | 4.0 | 29.3 |
| Tenderness | 4.0 | 43.3 |
| Erythema/redness | 0.0 | 2.7 |
| Induration | 0.0 | 3.3 |
| Swelling | 0.0 | 2.7 |
Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited local AEs included injection site pain, tenderness, erythema/redness, induration, and swelling.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Injection site pain | 2.0 | 50.0 |
| Tenderness | 4.1 | 62.7 |
| Erythema/redness | 0.0 | 15.3 |
| Induration | 0.0 | 11.3 |
| Swelling | 0.0 | 17.3 |
Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following first vaccination. Solicited systemic AEs included fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Fever | 0.0 | 0.0 |
| Fatigue | 6.0 | 8.7 |
| Malaise | 4.0 | 10.0 |
| Myalgia | 4.0 | 17.3 |
| Arthralgia | 0.0 | 4.7 |
| Nausea/vomiting | 0.0 | 0.7 |
| Headache | 2.0 | 10.7 |
Solicited systemic AEs were pre-defined AEs for which participants were specifically questioned and which were noted by participants in their diary for six subsequent days following second vaccination. Solicited systemic AEs included fever, fatigue, malaise, myalgia, arthralgia, nausea/vomiting and headache.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Fever | 0.0 | 6.0 |
| Fatigue | 8.2 | 20.7 |
| Malaise | 6.1 | 29.3 |
| Myalgia | 4.1 | 32.7 |
| Arthralgia | 0.0 | 13.3 |
| Nausea/vomiting | 0.0 | 5.3 |
| Headache | 2.0 | 21.3 |
Unsolicited AEs were all AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Unsolicited AEs for 20 Days Following First Vaccination | 8.0 | 10.0 |
Unsolicited AEs were all AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Unsolicited AEs for 27 Days Following Second Vaccination | 12.2 | 29.3 |
Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this outcome measure (OM) and solicited SAE was out of the scope of assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs until Day 50 were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Until Day 50 | 0.0 | 0.0 |
AESIs were defined as AEs that were specifically highlighted to the Investigator. Only unsolicited AESI data was planned to be collected and assessed for the assessment of this OM and solicited AESI was out of the scope of assessment. Unsolicited AESIs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited AESIs until Day 50 were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Adverse Events of Special Interest (AESI) Until Day 50 | 0.0 | 0.0 |
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAE was out of the scope of assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs until Day 50 were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Medically-Attended Adverse Events (MAAEs) Until Day 50 | 4.0 | 2.7 |
Only any unsolicited AE leading to discontinuation of vaccination data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to discontinuation of vaccination was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to discontinuation of vaccination until Day 22 were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Any AE Leading to Discontinuation of Vaccination | 2.0 | 0.0 |
Only any unsolicited AE leading to participant's withdrawal from the trial data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal from the trial was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to participant's withdrawal from the trial until Day 50 were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial Until Day 50 | 0.0 | 0.0 |
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Until Day 50 | 0.0 | 0.0 |
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below lower limit of quantification (LLOQ) were imputed to a value that was half of the LLOQ. LLOQ was equal to 200. Here, ELISA is Enzyme-linked immunosorbent assay.
| ELISA units per mL (EU/mL) | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Geometric Mean Titers (GMT) of Serum Immunoglobulin G (IgG) Antibody Levels to SARS-CoV-2 Recombinant Spike (rS) Protein on Day 36 | 132.3 (109.6 to 159.5) | 31036.8 (26837.1 to 35893.7) |
GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of study intervention.
| fold change | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Geometric Mean Fold Rise (GMFR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36 | 1.0 (1.0 to 1.1) | 258.8 (218.8 to 306.0) |
SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Seroconversion Rate (SCR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36 | 0.0 (0.0 to 7.3) | 100.0 (97.6 to 100.0) |
SRR was defined as percentage of participants with greater than or equal to (\>=) 95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Seroresponse Rate (SRR) of Serum IgG Antibody Levels to SARS-CoV-2 rS Protein on Day 36 | 8.2 (2.3 to 19.6) | 100.0 (97.6 to 100.0) |
Only unsolicited SAEs data was planned to be collected and assessed for the assessment of this OM and solicited SAE was out of the scope of assessment. Unsolicited SAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited SAEs throughout the trial were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With SAE Throughout the Trial | 2.0 | 0.0 |
AESIs were defined as AEs that were specifically highlighted to the Investigator. Only unsolicited AESI data was planned to be collected and assessed for the assessment of this OM and solicited AESI was out of the scope of assessment. Unsolicited AESI were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited AESIs throughout the trial were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With AESI Throughout the Trial | 0.0 | 0.0 |
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria. Only unsolicited MAAEs data was planned to be collected and assessed for the assessment of this OM and solicited MAAE was out of the scope of assessment. Unsolicited MAAEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with unsolicited MAAEs throughout the trial were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With MAAEs Throughout the Trial | 6.0 | 10.7 |
Only any unsolicited AE leading to participant's withdrawal from the trial data was planned to be collected and assessed for the assessment of this OM and solicited AE leading to participant's withdrawal from the trial was out of the scope of assessment. Unsolicited AEs were those AEs that were not pre-defined for which the participant was not specifically questioned in the participant diary. Percentage of participants with any unsolicited AE leading to withdrawal from the trial from the day of vaccination throughout the trial were reported in this outcome measure.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With Any AE Leading to Participant's Withdrawal From the Trial From the Day of Vaccination Throughout the Trial | 0.0 | 0.0 |
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Percentage of Participants With SARS-CoV-2 Infection Throughout the Trial | 2.0 | 2.7 |
GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. GMT of serum IgG antibody levels to the SARS-CoV-2 rS protein was measured where LLOQ was equal to 200.
| EU/mL | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Day 22 | 144.9 (115.2 to 182.4) | 1390.0 (1140.8 to 1693.7) |
| Day 50 | 134.7 (109.3 to 166.2) | 23910.8 (20737.0 to 27570.3) |
| Day 202 | 851.0 (26.0 to 27800.8) | 4390.1 (3600.9 to 5352.3) |
| Day 387 | 236.7 (15.2 to 3674.6) | 3461.2 (2601.5 to 4605.1) |
GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Where baseline was defined as the last measurement taken before the first dose of study intervention.
| fold change | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Day 22 | 1.1 (1.0 to 1.2) | 11.6 (9.4 to 14.2) |
| Day 50 | 1.0 (1.0 to 1.1) | 199.1 (169.2 to 234.3) |
| Day 202 | 8.5 (0.3 to 278.0) | 36.4 (29.8 to 44.6) |
| Day 387 | 2.4 (0.2 to 36.7) | 27.9 (20.7 to 37.6) |
SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Day 22 | 6.1 (1.3 to 16.9) | 82.7 (75.6 to 88.4) |
| Day 50 | 2.0 (0.1 to 10.9) | 100.0 (97.6 to 100.0) |
| Day 202 | 33.3 (4.3 to 77.7) | 97.9 (94.1 to 99.6) |
| Day 387 | 25.0 (0.6 to 80.6) | 96.9 (92.1 to 99.1) |
SRR was defined as percentage of participants with \>=95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Day 22 | 10.2 (3.4 to 22.2) | 84.0 (77.1 to 89.5) |
| Day 50 | 12.2 (4.6 to 24.8) | 100.0 (97.6 to 100.0) |
| Day 202 | 33.3 (4.3 to 77.7) | 97.9 (94.1 to 99.6) |
| Day 387 | 25.0 (0.6 to 80.6) | 96.9 (92.1 to 99.1) |
The neutralization titer was expressed as the reciprocal of the highest dilution at which greater than or equal to (\>=) 50% of the replicate wells were protected from infection (MN50). GMT was the immunogenicity outcome expressed as reciprocal antibody titer with average for each group. Titer values was measured as below LLOQ were imputed to a value that was half of the LLOQ. GMT of serum IgG antibody levels to the SARS-CoV-2 rS protein was measured where LLOQ was equal to 20.
| 1 per dilution | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Day 22 | 10.4 (9.9 to 10.9) | 50.2 (41.2 to 61.0) |
| Day 36 | 10.4 (9.9 to 10.9) | 884.4 (749.0 to 1044.4) |
| Day 50 | 10.4 (9.9 to 10.9) | 509.5 (422.5 to 614.6) |
| Day 202 | 50.4 (3.6 to 698.8) | 65.5 (53.4 to 80.4) |
| Day 387 | 14.1 (4.7 to 42.6) | 65.7 (49.0 to 88.1) |
The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). GMFR was calculated as the ratio of the post-vaccination titer level to the baseline titer level. Baseline was defined as the last measurement taken before the first dose of study intervention.
| fold change | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Day 22 | 1.0 (1.0 to 1.1) | 5.0 (4.1 to 6.1) |
| Day 36 | 1.0 (1.0 to 1.1) | 88.0 (74.5 to 104.0) |
| Day 50 | 1.0 (1.0 to 1.1) | 50.7 (42.0 to 61.2) |
| Day 202 | 5.0 (0.4 to 69.9) | 6.5 (5.3 to 8.0) |
| Day 387 | 1.4 (0.5 to 4.3) | 6.5 (4.9 to 8.7) |
The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). SCR was defined as percentage of participants with 4-fold or more rises in titer if naive at baseline OR percentage of participants with 2-fold or more rises in titer if seropositive at Baseline. Baseline was defined as the last measurement taken before the first dose of study intervention.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Day 22 | 0.0 (0.0 to 7.3) | 67.3 (59.2 to 74.8) |
| Day 36 | 0.0 (0.0 to 7.3) | 99.3 (96.3 to 100.0) |
| Day 50 | 0.0 (0.0 to 7.3) | 98.0 (94.2 to 99.6) |
| Day 202 | 33.3 (4.3 to 77.7) | 76.0 (68.3 to 82.7) |
| Day 387 | 25.0 (0.6 to 80.6) | 70.9 (62.1 to 78.6) |
The neutralization titer was expressed as the reciprocal of the highest dilution at which \>=50% of the replicate wells were protected from infection (MN50). SRR was defined as percentage of participants with \>=95 percentile in titer at Baseline for all participants. Baseline was defined as the last measurement taken before the first dose of study intervention.
| percentage of participants | Placebo | TAK-019 0.5 mL |
|---|---|---|
| Day 22 | 100.0 (92.7 to 100.0) | 100.0 (97.6 to 100.0) |
| Day 36 | 100.0 (92.7 to 100.0) | 100.0 (97.6 to 100.0) |
| Day 50 | 100.0 (92.7 to 100.0) | 100.0 (97.6 to 100.0) |
| Day 202 | 100.0 (54.1 to 100.0) | 100.0 (97.5 to 100.0) |
| Day 387 | 100.0 (39.8 to 100.0) | 100.0 (97.1 to 100.0) |
Collected over Treatment-emergent adverse events (TEAEs) are AEs that started after the first vaccination on Day 1 up to 365 days after the second vaccination on Day 22 (Day 387). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/50 (0%) | 1/50 (2%) | 11/50 (22%) |
| TAK-019 | 0/150 (0%) | 0/150 (0%) | 124/150 (82.7%) |
| Event | Placebo | TAK-019 |
|---|---|---|
| COVID-19Infections and infestations | 1/50 | 0/150 |
| Event | Placebo | TAK-019 |
|---|---|---|
| TendernessGeneral disorders | 3/50 | 100/150 |
| Injection site painGeneral disorders | 3/50 | 88/150 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/50 | 56/150 |
| MalaiseGeneral disorders | 6/50 | 50/150 |
| HeadacheNervous system disorders | 2/50 | 41/150 |
| FatigueGeneral disorders | 7/50 | 39/150 |
| SwellingGeneral disorders | 0/50 | 27/150 |
| Injection site pruritusGeneral disorders | 0/50 | 26/150 |
| Vaccination site erythemaGeneral disorders | 0/50 | 26/150 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/50 | 24/150 |
The safety analysis set included all participants who received at least 1 dose of the treatment.
| Age, Continuous(years) | Placebo | TAK-019 0.5 mL | Total |
|---|---|---|---|
| Mean | 50.8 ± 16.42 | 52.6 ± 15.80 | 52.2 ± 15.93 |
| Sex: Female, Male(Participants) | Placebo | TAK-019 0.5 mL | Total |
|---|---|---|---|
| Female | 21 | 65 | 86 |
| Male | 29 | 85 | 114 |
| Race/Ethnicity, Customized(Participants) | Placebo | TAK-019 0.5 mL | Total |
|---|---|---|---|
| Japanese | 50 | 150 | 200 |
| Region of Enrollment(Participants) | Placebo | TAK-019 0.5 mL | Total |
|---|---|---|---|
| Japan | 50 | 150 | 200 |
| Weight(kilogram (kg)) | Placebo | TAK-019 0.5 mL | Total |
|---|---|---|---|
| Mean | 61.73 ± 11.806 | 62.94 ± 10.485 | 62.64 ± 10.813 |
| Height(centimeter (cm)) | Placebo | TAK-019 0.5 mL | Total |
|---|---|---|---|
| Mean | 164.00 ± 9.157 | 164.10 ± 8.596 | 164.08 ± 8.716 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Placebo | TAK-019 0.5 mL | Total |
|---|---|---|---|
| Mean | 22.80 ± 2.865 | 23.29 ± 2.850 | 23.17 ± 2.854 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2021 to primary completion in Mar 2022, 13 months.
Results were first posted in Jun 2023, 1 year 2 months after primary completion.
Of 11 phase 1/2 interventional studies under Severe Acute Respiratory Syndrome, half reached primary completion within 5 months of starting (the median); a quarter within 3 and three quarters within 13. This study's 13 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle
Severe Acute Respiratory Syndrome →